BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32321643)

  • 1. Serine mutation of a conserved threonine in the hERG K
    Al-Moubarak E; Zhang Y; Dempsey CE; Zhang H; Harmer SC; Hancox JC
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1085-1091. PubMed ID: 32321643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological characterization of the modified hERG
    Zhang Y; Dempsey CE; Hancox JC
    Physiol Rep; 2020 Oct; 8(20):e14568. PubMed ID: 33091232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
    Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
    Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
    Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
    Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating pro-arrhythmogenic effects of the T634S-hERG mutation: insights from a simulation study.
    Hu W; Zhang W; Zhang K; Al-Moubarak E; Zhang Y; Harmer SC; Hancox JC; Zhang H
    Interface Focus; 2023 Dec; 13(6):20230035. PubMed ID: 38106919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
    Du C; Zhang H; Harmer SC; Hancox JC
    Biochem Biophys Res Commun; 2022 Mar; 596():49-55. PubMed ID: 35114584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
    Ridley JM; Milnes JT; Hancox JC; Witchel HJ
    J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
    Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
    J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Ro52 antibody acts on the S5-pore linker of hERG to chronically reduce channel expression.
    Szendrey J; Lamothe SM; Vanner S; Guo J; Yang T; Li W; Davis J; Joneja M; Baranchuk A; Zhang S
    Cardiovasc Res; 2019 Aug; 115(10):1500-1511. PubMed ID: 30544220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration.
    Melgari D; Du C; El Harchi A; Zhang Y; Hancox JC
    Physiol Rep; 2014 Oct; 2(10):. PubMed ID: 25318749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
    Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
    Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Effects of Remdesivir and Lumacaftor on Homomeric and Heteromeric hERG Channels.
    Campagna N; Wall E; Lee K; Guo J; Li W; Yang T; Baranchuk A; El-Diasty M; Zhang S
    Mol Pharmacol; 2023 Oct; 104(4):164-173. PubMed ID: 37419691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant.
    Al-Moubarak E; Shiels HA; Zhang Y; Du C; Hanington O; Harmer SC; Dempsey CE; Hancox JC
    Cell Mol Life Sci; 2021 Dec; 78(23):7899-7914. PubMed ID: 34727194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fentanyl-Induced Block of hERG Channels Is Exacerbated by Hypoxia, Hypokalemia, Alkalosis, and the Presence of hERG1b.
    Tschirhart JN; Zhang S
    Mol Pharmacol; 2020 Oct; 98(4):508-517. PubMed ID: 32321735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel characteristics of a trafficking-defective G572R-hERG channel linked to hereditary long QT syndrome.
    Lian J; Huang N; Zhou J; Ge S; Huang X; Huo J; Liu L; Xu W; Zhang S; Yang X; Zhou J; Huang C
    Can J Cardiol; 2010 Oct; 26(8):417-22. PubMed ID: 20931094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mutation in KCNH2 yields loss-of-function of hERG potassium channel in long QT syndrome 2.
    Gu K; Qian D; Qin H; Cui C; Fernando WCHA; Wang D; Wang J; Cao K; Chen M
    Pflugers Arch; 2021 Feb; 473(2):219-229. PubMed ID: 33449212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Regulation of Human Ether-à-Go-Go-Related Gene (hERG) Current and Expression by Activation of Protein Kinase C.
    Sutherland-Deveen ME; Wang T; Lamothe SM; Tschirhart JN; Guo J; Li W; Yang T; Du Y; Zhang S
    Mol Pharmacol; 2019 Jul; 96(1):1-12. PubMed ID: 31015282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Approach to Defective Protein Trafficking in the E637K-hERG Mutant with PD-118057 and Thapsigargin.
    Mao H; Lu X; Karush JM; Huang X; Yang X; Ba Y; Wang Y; Liu N; Zhou J; Lian J
    PLoS One; 2013; 8(6):e65481. PubMed ID: 23840331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome.
    Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
    Heliyon; 2019 Apr; 5(4):e01429. PubMed ID: 31049424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.